Nutrition for Precision Health, Powered by the All of Us

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
RTI International
Study ID
NCT05701657
Status
Recruiting

Conditions

  • Dietary Habits
  • Health
  • Nutrition

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Diet A — OTHER
    This diet has high amounts of fruits/vegetables, whole grains, and beans, moderate amounts of dairy, meat/poultry/eggs, nuts/seeds, and olive oil, and very low amounts of sugar sweetened drinks and desserts.
  • Diet B — OTHER
    This diet has high amounts of refined grains, meat/poultry/egg, sugar sweetened drinks, snacks, desserts, and processed foods. It has a moderate amount of dairy and low amounts of fruits/vegetables, whole grains, and fish.
  • Diet C — OTHER
    This diet has moderate-high amounts of vegetables, meat/poultry/egg, nuts/seeds, dairy and fats/oils, low amounts of fruits, and very low amounts of grains and sugars.

Study Details

The goal of this Nutrition for Precision Health (NPH) powered by All of Us research study is to develop Artificial Intelligence/Machine Learning (AI/ML) algorithms that predict individual responses to diet patterns using rich multimodal data streams collected across multiple domains (e.g., behavior, social, environmental, clinical and molecular biomarkers). NPH includes a large phenotyping cohort (Module 1, N=8000) and two separate follow-up groups drawn from a subset of Module 1participants. One group (Module 2, N=1200) receives three distinct diets in a 14-day crossover sequence, with at least a 14-day washout period between diets, while living in their own homes. A second group (Module 3, N=150) receives the same three diets under full-time supervision in a residential research setting. We will train and test AI/ML models to predict 0-4 hour postprandial response curves for glucose, insulin, triglycerides, and GLP-1, to the standardized diet-specific meal test (DSMT) collected after each of the three different diets delivered in Module 2. Each diet functions as a controlled stimulus to reveal biological features (such as individual variables, patterns, or clusters of measurements) that best predict a person's response. The Module 2 DSMT response curves are the primary outcomes (dependent variables) for AI/ML algorithms that predict individual responses to diet patterns. As a secondary objective, NPH will evaluate the validity and acceptability of technology-based dietary assessment tools. The Automated Self-Administered 24-hour recall (ASA24), Automatic Ingestion Monitor-2 (AIM-2), and the mobile food record (mFR) will be evaluated in Modules 2 and 3, and the ASA24 food record and the image-assisted ASA24 recall will be evaluated only in Module 3. Total energy intake, macronutrient and dietary fiber intake data are the main outcomes for validity testing compared against measures of actual intake. Acceptability will be determined from feedback surveys.

Key Dates

Start date
Apr 14, 2023
Status verified
Jun 2026
Primary completion
Dec 31, 2026
Completion
Jan 31, 2027

Study Design

Enrollment
8,000 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER

Arms

  • Experimental: Community-Dwelling Controlled-Feeding Arm (Module 2)
    Participants drawn from Module 1 will receive three standardized diets (A, B, and C) in one of six sequences. Diet sequences are assigned at the cohort level based on a pre-defined site-specific schedule. All meals are provided while participants remain living in their own homes. Each diet period lasts \~14 days, separated by washouts of at least 14 days. Participants are masked to the nutritional content of each diet. Data collection includes wearable device outputs, physical and contextual assessments, and biospecimens. This arm evaluates metabolic responses to controlled diets under real-world, community-dwelling conditions.
  • Experimental: Residential Controlled-Feeding Arm (Module 3)
    A separate group of participants drawn from Module 1, who are not enrolled in Module 2, will receive the same three standardized diets administered in Module 2 while residing in a fully supervised residential setting. Diet sequences are assigned at the cohort level based on a pre-defined site-specific schedule. Each diet period will last approximately 14 days and will be separated by washout periods of at least 14 days. Intake, activity, and sleep will be closely monitored. Participants will also complete the same liquid meal test administered in Module 1 (see detailed description) after each of the diet periods. A wealth of measurements will be collected, including data from wearables, physical and contextual measures, and biospecimens. Intake balance studies are conducted in this module using the doubly labeled water assessments and DXA for body composition. Module 3 is designed to isolate the response to different diets from behavioral variability observed in community settings.

Primary Outcome Measure

Glucose - Diet Specific mixed meal tolerance test (MMTT) Diet A [ Time Frame: 4 hours ]

Central Contacts

Locations (14)

FacilityCityStateZIPSite coordinators
University of Alabama at BirminghamBirminghamAlabama35233
Sarah Ehrlicher, PhD, RDN
205-934-0027
James Hill, PhD (PRINCIPAL_INVESTIGATOR)
Barbara Gower, PhD (SUB_INVESTIGATOR)
University of California, DavisDavisCalifornia95616
Ellen Bonnel
530-723-2568
Alexander Borowsky, MD (SUB_INVESTIGATOR)
Sean Adams, PhD (PRINCIPAL_INVESTIGATOR)
Francene Steinberg, PhD, RD (SUB_INVESTIGATOR)
USDA Western Human Nutrition Research CenterDavisCalifornia95616
Ellen Bonnel
530-723-2568
Brian Bennett, PhD (PRINCIPAL_INVESTIGATOR)
University of California, Los AngelesLos AngelesCalifornia90024
Jeraldine Guzman
310-206-8292
Zhaoping Li, MD (PRINCIPAL_INVESTIGATOR)
Cedars Sinai Medical CenterWest HollywoodCalifornia90069
Christina Lombardi, PhD
310-423-1001
Marc Goodman, PhD (SUB_INVESTIGATOR)
Illinois Institute of TechnologyChicagoIllinois60616
Illinois Institute of Technology
312-567-5300
Linda Van Horn, PhD, RD, LDN (PRINCIPAL_INVESTIGATOR)
Britt Burton-Freeman, PhD (SUB_INVESTIGATOR)
Northwestern UniversityChicagoIllinois60611
Northwestern Medicine
312-695-6077
Linda Van Horn, PhD, RD, LDN (PRINCIPAL_INVESTIGATOR)
Joyce Ho, PhD (SUB_INVESTIGATOR)
Marilyn Cornelis, PhD (SUB_INVESTIGATOR)
University of ChicagoChicagoIllinois60637
Kendall Bahl
773-795-3484
Linda Van Horn, Phd, RD, LDN (PRINCIPAL_INVESTIGATOR)
Briseis Aschebrook-Kilfoy, PhD (SUB_INVESTIGATOR)
Pennington Biomedical Research CenterBaton RougeLouisiana70808
Melissa Harris, MPA
225-763-3091
Eric Ravussin, PhD (PRINCIPAL_INVESTIGATOR)
Leanne Redman, PhD (SUB_INVESTIGATOR)
Louisiana State University Health Sciences CenterNew OrleansLouisiana70112
Connie Romaine, NP, RN
504-568-5111
Eric Ravussin, PhD (PRINCIPAL_INVESTIGATOR)
Leanne Redman, PhD (SUB_INVESTIGATOR)
Massachusetts General HospitalBostonMassachusetts02114
Jessica McGoldrick, MBA
617-724-6503
Sai Das, PhD (PRINCIPAL_INVESTIGATOR)
Hamed Khalili, MD, MPH (SUB_INVESTIGATOR)
Tufts UniversityBostonMassachusetts02111
Paul Fuss
617-556-3381
Sai Das, PhD (PRINCIPAL_INVESTIGATOR)
Hamed Khalili, MD, MPH (SUB_INVESTIGATOR)
University of North Carolina at Chapel Hill - Chapel Hill ClinicChapel HillNorth Carolina27514
Joan Thomas, MS, RD
800-561-0315
919-808-5686
Elizabeth Mayer-Davis, Phd, RD (PRINCIPAL_INVESTIGATOR)
University of North Carolina at Chapel Hill - KannapolisKannapolisNorth Carolina28081
Julie Stegall, MSW
800-561-0315
704-928-1277
Elizabeth Mayer-Davis, PhD, RD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Birmingham, AL

Related Studies